Rubén received a Doctorate in chemistry and biochemistry from UCLA and soon after began his career in the San Diego biotechnology industry at BD Biosciences Pharmigen. Rubén has held a variety of positions with increasing responsibility in R&D, marketing, business development and technology commercialization. His professional career includes Biosite (now Alere), where he helped design, initiate, negotiate and monitor clinical trials; Rubén later joined Chemicon (now Millipore-Sigma), where he managed R&D, worldwide clinical-trial operations, and marketing activities for diagnostic products. While at Millipore-Sigma, Rubén also founded the world-wide Scientific Collaborations and Business Development group, tasked with working with academic partners across the globe for the development of early-stage academic research in a multitude of areas including stem cell research, biomarkers, cancer, neuroscience, diagnostics, therapeutics and microfluidics.
Most recently, Rubén served as Vice President of Business Development and Technology Transfer for the Los Angeles BioMedical Research Institute at Harbor UCLA Medical Center, where he focused on fostering the entrepreneurial ecosystem for startups in Los Angeles working with local academic centers, the County of Los Angeles, LAEDC, LARTA, BIOCOM and local REITs.
Rubén has lent his expertise to the Southern California life sciences industry as a past member of BIOCOM’s FDA committee. In addition, Rubén acted as a member of the Scientific Advisory board of UC Riverside’s department of Bioengineering, the advisory board to the Coulter Translational Research Partnership Program at the departments of Bioengineering at the University of Washington and at the University of Southern California, and the advisory board for graduate programs in Biotechnology at Cal State University San Marcos.